EP1825005A4 - Mer diagnostic and therapeutic agents - Google Patents

Mer diagnostic and therapeutic agents

Info

Publication number
EP1825005A4
EP1825005A4 EP05852182A EP05852182A EP1825005A4 EP 1825005 A4 EP1825005 A4 EP 1825005A4 EP 05852182 A EP05852182 A EP 05852182A EP 05852182 A EP05852182 A EP 05852182A EP 1825005 A4 EP1825005 A4 EP 1825005A4
Authority
EP
European Patent Office
Prior art keywords
therapeutic agents
mer
diagnostic
mer diagnostic
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP05852182A
Other languages
German (de)
French (fr)
Other versions
EP1825005B1 (en
EP1825005A2 (en
Inventor
Douglas Kim Graham
Susan Louise Sather
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Colorado
Original Assignee
University of Colorado
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Colorado filed Critical University of Colorado
Publication of EP1825005A2 publication Critical patent/EP1825005A2/en
Publication of EP1825005A4 publication Critical patent/EP1825005A4/en
Application granted granted Critical
Publication of EP1825005B1 publication Critical patent/EP1825005B1/en
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP05852182.4A 2004-11-24 2005-11-23 Mer diagnostic and therapeutic agents Not-in-force EP1825005B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63019204P 2004-11-24 2004-11-24
PCT/US2005/042724 WO2006058202A2 (en) 2004-11-24 2005-11-23 Mer diagnostic and therapeutic agents

Publications (3)

Publication Number Publication Date
EP1825005A2 EP1825005A2 (en) 2007-08-29
EP1825005A4 true EP1825005A4 (en) 2009-04-01
EP1825005B1 EP1825005B1 (en) 2015-07-15

Family

ID=36498546

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05852182.4A Not-in-force EP1825005B1 (en) 2004-11-24 2005-11-23 Mer diagnostic and therapeutic agents

Country Status (5)

Country Link
US (2) US20080267975A1 (en)
EP (1) EP1825005B1 (en)
JP (1) JP2008522162A (en)
CA (1) CA2630475A1 (en)
WO (1) WO2006058202A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4854070B2 (en) * 2004-01-29 2012-01-11 旭化成ファーマ株式会社 Treatment for vasospasm associated with bypass surgery
US8168415B2 (en) 2007-02-07 2012-05-01 The Regents Of The University Of Colorado Axl fusion proteins as Axl tyrosine kinase inhibitors
PT3241840T (en) * 2010-01-22 2022-10-13 Univ Leland Stanford Junior Inhibition of axl signaling in anti-metastatic therapy
WO2012149018A1 (en) * 2011-04-25 2012-11-01 The Regents Of The University Of Colorado Mer tyrosine kinase inhibitors and methods of making and using the same
US9879061B2 (en) 2011-12-15 2018-01-30 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis
US9822347B2 (en) 2012-12-14 2017-11-21 The Board Of Trustees Of The Leland Stanford Junior University Modified AXL peptides and their use in inhibition of AXL signaling in anti-metastatic therapy
KR20150040766A (en) * 2013-10-07 2015-04-15 이화여자대학교 산학협력단 A method for screening anti-inflammatory material
US10137173B2 (en) 2014-10-20 2018-11-27 Aravive Biologics, Inc. Antiviral activity of Gas6 inhibitor
EP3237450B1 (en) 2014-12-22 2021-03-03 The Rockefeller University Anti-mertk agonistic antibodies and uses thereof
US11613588B2 (en) 2017-06-28 2023-03-28 The Rockefeller University Anti-mertk agonistic antibodies and uses thereof
US11897968B2 (en) 2019-12-13 2024-02-13 Alector Llc Anti-MerTK antibodies and methods of use thereof
CN111812014B (en) * 2020-08-05 2023-04-18 上海市血液中心 Platelet antibody detection method and platelet preservation method based on nano material
US20240279358A1 (en) 2021-06-16 2024-08-22 Alector Llc Monovalent anti-mertk antibodies and methods of use thereof
CN117642426A (en) 2021-06-16 2024-03-01 艾莱克特有限责任公司 Bispecific anti-MerTK and anti-PDL 1 antibodies and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995033499A1 (en) * 1994-06-02 1995-12-14 The University Of North Carolina At Chapel Hill Isolated dna encoding c-mer protooncogene

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US6018026A (en) * 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
US5554601A (en) * 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
US7339033B2 (en) * 1998-06-26 2008-03-04 Genentech, Inc. Pro1481
US20030144237A1 (en) * 2000-04-13 2003-07-31 Peter Carmeliet Use of inhibition of a gas6 function or of a gas6 receptor for preventing and treating a cardiovascular disease
US20040018513A1 (en) * 2002-03-22 2004-01-29 Downing James R Classification and prognosis prediction of acute lymphoblastic leukemia by gene expression profiling
US20040157774A1 (en) * 2002-09-24 2004-08-12 Jing Yang Epitope-tagged recombinant Growth Arrest Specific Gene 6 protein

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995033499A1 (en) * 1994-06-02 1995-12-14 The University Of North Carolina At Chapel Hill Isolated dna encoding c-mer protooncogene

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
COHEN PHILIP L ET AL: "Delayed apoptotic cell clearance and lupus-like autoimmunity in mice lacking the c-mer membrane tyrosine kinase.", THE JOURNAL OF EXPERIMENTAL MEDICINE 1 JUL 2002, vol. 196, no. 1, 1 July 2002 (2002-07-01), pages 135 - 140, XP002515128, ISSN: 0022-1007 *
EK SARA ET AL: "Mantle cell lymphomas express a distinct genetic signature affecting lymphocyte trafficking and growth regulation as compared with subpopulations of normal human B cells.", CANCER RESEARCH 1 AUG 2002, vol. 62, no. 15, 1 August 2002 (2002-08-01), pages 4398 - 4405, XP002515126, ISSN: 0008-5472 *
FENG WEI ET AL: "Mertk triggers uptake of photoreceptor outer segments during phagocytosis by cultured retinal pigment epithelial cells.", THE JOURNAL OF BIOLOGICAL CHEMISTRY 10 MAY 2002, vol. 277, no. 19, 10 May 2002 (2002-05-10), pages 17016 - 17022, XP002515127, ISSN: 0021-9258 *
GRAHAM DOUGLAS K ET AL: "Ectopic expression of the proto-oncogene Mer in pediatric T-cell acute lymphoblastic leukemia.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 1 MAY 2006, vol. 12, no. 9, 1 May 2006 (2006-05-01), pages 2662 - 2669, XP002515129, ISSN: 1078-0432 *
SALZBERG DANA B ET AL: "Lymphoblastic leukemia/lymphoma in mice overexpressing the Mer receptor tyrosine kinase.", BLOOD, vol. 106, no. 11, Part 1, November 2005 (2005-11-01), & 47TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; ATLANTA, GA, USA; DECEMBER 10 -13, 2005, pages 736A, XP002515130, ISSN: 0006-4971 *

Also Published As

Publication number Publication date
CA2630475A1 (en) 2006-06-01
WO2006058202A2 (en) 2006-06-01
JP2008522162A (en) 2008-06-26
US20120135424A1 (en) 2012-05-31
US20080267975A1 (en) 2008-10-30
WO2006058202A3 (en) 2007-06-07
EP1825005B1 (en) 2015-07-15
EP1825005A2 (en) 2007-08-29

Similar Documents

Publication Publication Date Title
EP1825005A4 (en) Mer diagnostic and therapeutic agents
EP1758605A4 (en) Prouroguanylin as therapeutic and diagnostic agents
EP1874800A4 (en) Diagnostic and therapeutic agents
EP1781685A4 (en) Therapeutic and diagnostic agents
GB0416396D0 (en) Therapeutic agents
GB0419850D0 (en) Therapeutic agents
EP1572741A4 (en) Therapeutic and diagnostic agents
GB0403780D0 (en) Therapeutic agents
GB0419192D0 (en) Therapeutic agents
GB0423103D0 (en) Therapeutic agents
GB0407382D0 (en) Therapeutic methods and means
EP1951914A4 (en) Diagnostic and therapeutic methods and agents
EP1603535A4 (en) Aromatase inhibitor diagnosis and therapy
GB0512726D0 (en) Multiple sclerosis therapy and diagnosis
EP1701736A4 (en) Therapeutic agents and uses therefor
GB0402129D0 (en) Therapeutic and diagnostic peptides
GB0417939D0 (en) Therapeutic agents
GB0400193D0 (en) Therapeutic agents
GB0427701D0 (en) Therapeutic agents
AU2004904133A0 (en) Therapeutic and diagnostic agents
AU2004907069A0 (en) Therapeutic and diagnostic agents
GB0416934D0 (en) Therapeutic agents
GB0400196D0 (en) Therapeutic agents
GB0402918D0 (en) Therapeutic agents
GB0403779D0 (en) Therapeutic agents

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070621

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1108289

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20090304

17Q First examination report despatched

Effective date: 20090708

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE REGENTS OF THE UNIVERSITY OF COLORADO

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602005046995

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: C12Q0001700000

Ipc: A61K0039395000

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/30 20060101ALI20120227BHEP

Ipc: G01N 33/53 20060101ALI20120227BHEP

Ipc: C07K 16/28 20060101ALI20120227BHEP

Ipc: G01N 33/86 20060101ALI20120227BHEP

Ipc: G01N 33/574 20060101ALI20120227BHEP

Ipc: A61K 39/395 20060101AFI20120227BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1108289

Country of ref document: HK

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20150205

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 736432

Country of ref document: AT

Kind code of ref document: T

Effective date: 20150815

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602005046995

Country of ref document: DE

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 736432

Country of ref document: AT

Kind code of ref document: T

Effective date: 20150715

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20150715

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150715

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150715

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150715

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151016

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150715

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151116

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150715

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150715

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150715

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151115

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602005046995

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150715

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150715

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150715

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150715

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150715

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150715

26N No opposition filed

Effective date: 20160418

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151123

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150715

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151130

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151130

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150715

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151123

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150715

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20161128

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20161227

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20161229

Year of fee payment: 12

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20051123

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150715

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150715

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150715

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150715

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602005046995

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20171123

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20180731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171130

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180602

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171123